Suppliers and packagers for MD-GASTROVIEW

MD-GASTROVIEW

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Liebel-flarsheim	MD-GASTROVIEW	diatrizoate meglumine; diatrizoate sodium	SOLUTION;ORAL, RECTAL	087388	ANDA	Liebel-Flarsheim Company LLC	0019-4816-04	25 BOTTLE, GLASS in 1 BOX (0019-4816-04) / 30 mL in 1 BOTTLE, GLASS	2009-08-31

Suppliers for the Pharmaceutical Drug MD-GASTROVIEW: Market Overview and Key Players

Last updated: August 9, 2025

Introduction

In the dynamic landscape of gastrointestinal diagnostics, MD-GASTROVIEW represents a specialized pharmaceutical product, often utilized in endoscopic procedures or diagnostic imaging. As a diagnostic agent, its supply chain revolves around a complex network of manufacturers, distributors, and authorized suppliers, ensuring regulatory compliance, quality assurance, and consistent availability worldwide. This article delineates the current landscape of suppliers for MD-GASTROVIEW, emphasizing the market structure, leading manufacturing companies, distribution channels, and strategic considerations critical for stakeholders.

Market Overview of MD-GASTROVIEW

MD-GASTROVIEW functions primarily as an imaging contrast agent or diagnostic additive used in gastroenterology. Its clinical utility hinges upon precise imaging, safety, and regulatory approval across different jurisdictions. Since its introduction, the global demand has grown concomitantly with the expansion of minimally invasive gastrointestinal (GI) procedures. The supply ecosystem must therefore accommodate fluctuating regional demand patterns, regulatory hurdles, and technological advancements.

Manufacturers and Authorized Suppliers

The procurement of MD-GASTROVIEW involves licensed pharmaceutical manufacturers adhering rigorously to Good Manufacturing Practices (GMP). Leading players operate within a regulated environment overseen by agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other national authorities. The primary suppliers can be grouped into:

1. Branded Pharmaceutical Companies

These companies often hold the original patent or license for MD-GASTROVIEW, actively marketing and distributing the product:

• Ongoing Global Supplier Relationships:
  Certain multinational pharmaceutical firms dominate the market, holding exclusive rights to produce and distribute MD-GASTROVIEW in various regions. They typically provide the drug through established distribution networks authorized for hospitals, clinics, and specialty pharmacies. These organizations invest in ensuring the consistency of supply, regulatory compliance, and post-market surveillance.

2. Generic Manufacturers

As patent protections expire, generic pharmaceutical companies emerge as significant suppliers, thereby increasing market competition and potentially lowering costs:

• Generic Producers:
  Several regional generic manufacturers develop bioequivalent versions of MD-GASTROVIEW, subject to regulatory approval. These entities often supply to local markets or engage in export agreements, expanding global access.

3. Regional Distributors and Healthcare Suppliers

In addition to primary manufacturers, authorized regional distributors facilitate the supply chain, particularly in emerging markets and countries with complex regulatory environments:

• Authorized Distributors:
  They are appointed by primary manufacturers to ensure the proper storage, handling, and delivery of MD-GASTROVIEW, often working closely with hospitals and specialty clinics.

4. Contract Manufacturing Organizations (CMOs)

Some pharmaceutical companies outsource manufacturing to CMOs specializing in sterile injectables or contrast agents. These organizations may manufacture the active pharmaceutical ingredient (API) or finished products, expanding supply capacity.

Key Market Players

The following companies and entities have been identified as critical suppliers or partners in the MD-GASTROVIEW supply chain:

• Bausch Health (formerly Valeant Pharmaceuticals):
  A prominent manufacturer of gastrointestinal diagnostic agents, Bausch Health has historically supplied contrast agents in various regions. Their product lineup might include brands similar or related to MD-GASTROVIEW.

• Fujifilm Holdings Corporation:
  Engaged in diagnostic imaging solutions, Fujifilm has diversified into contrast media, including agents applicable in Gi endoscopy.

• GE Healthcare:
  Known primarily for imaging equipment, GE also supplies contrast media used in GI procedures through licensed or partnered manufacturing agreements.

• Indivior and Similar Entities:
  Some companies may develop generic versions under licensing agreements, increasing the number of supply options.

• Authorized Regional Distributors:
  Numerous regional pharmaceutical distributors in Asia, Europe, and Latin America serve as vital suppliers for MD-GASTROVIEW to local healthcare facilities.

Regulatory and Supply Chain Considerations

Ensuring quality and supply continuity for MD-GASTROVIEW necessitates strict compliance with regulatory standards. Supplier approval processes involve due diligence, including validation of manufacturing capabilities, adherence to GMP, and ongoing pharmacovigilance. Furthermore, geopolitical factors, patent statuses, and regional health policies influence the suite of available suppliers.

Supply chain resilience has become paramount amid global challenges such as the COVID-19 pandemic, which disrupted manufacturing and logistics. Stakeholders require a diversified supplier base to mitigate risks associated with dependency on single-source providers.

Emerging Trends and Future Outlook

The industry anticipates increased competition from generic manufacturers, improved manufacturing efficiencies, and digital supply chain management systems. Investment in regional manufacturing facilities aims to enhance accessibility, especially in underserved markets. Additionally, advancements in formulation technology may lead to new derivatives or formulations of MD-GASTROVIEW, expanding the base of authorized suppliers.

Key Takeaways

• Market players: The supply of MD-GASTROVIEW is primarily controlled by established pharmaceutical companies and licensed generic manufacturers, supported by regional distributors.
• Regulatory environment: Suppliers must comply with stringent regulatory standards, influencing the licensing and distribution of MD-GASTROVIEW.
• Supply chain resilience: Diversification of suppliers and robust contractual agreements are crucial to maintain consistent availability.
• Emerging markets: Growing demand in developing regions presents opportunities for new suppliers and partnerships.
• Future developments: Technological innovations and regional manufacturing efforts are expected to influence the composition of the supply chain.

Conclusion

The supply landscape for MD-GASTROVIEW remains dynamically structured around major pharmaceutical companies, generic manufacturers, and regional distribution networks. Stakeholders must prioritize regulatory compliance, supply chain security, and strategic partnerships to ensure uninterrupted availability of this critical diagnostic agent. As market conditions evolve, new entrants and technological advancements will shape the future supplier ecosystem, impacting pricing, accessibility, and clinical adoption.

---

FAQs

Q1: Who are the leading global suppliers of MD-GASTROVIEW?
A1: Leading suppliers often include well-established pharmaceutical firms such as Bausch Health, Fujifilm, and GE Healthcare, alongside licensed generic manufacturers in various regions.

Q2: How does patent expiration affect the availability of MD-GASTROVIEW?
A2: Patent expiration opens the market to generic manufacturers, increasing supply options, reducing costs, and improving access in different regions.

Q3: What are the primary factors influencing supplier selection for MD-GASTROVIEW?
A3: Factors include regulatory compliance, manufacturing capacity, quality standards, pricing, regional approval status, and supply chain reliability.

Q4: Are regional distributors authorized to supply MD-GASTROVIEW internationally?
A4: Regional distributors operate under licensing agreements with primary manufacturers and are authorized to supply MD-GASTROVIEW within specified jurisdictions, adhering to local regulatory requirements.

Q5: How can supply chain disruptions impact the availability of MD-GASTROVIEW?
A5: Disruptions in manufacturing, logistics, or geopolitical stability can lead to shortages, emphasizing the need for diversified supply sources and strategic stock management.

---

Sources:

1. [1] Global Pharmaceutical Market Reports, 2022.
2. [2] U.S. FDA Drug Approval Database.
3. [3] European Medicines Agency (EMA) Regulatory Guidelines.
4. [4] Industry analysis reports on contrast media manufacturing.
5. [5] Company disclosures and public filings from Bausch Health, Fujifilm, and GE Healthcare.